You just read:

Ardea Biosciences to Present Additional Data From Completed Phase 2b Combination Study of Lesinurad (RDEA594) and Allopurinol at the Annual European Congress of Rheumatology

News provided by

Ardea Biosciences, Inc.

Apr 25, 2011, 09:00 ET